To investigate the function of EGFR mutations involving the tyrosine kinase domain in NSCLC, we used three NSCLC cell lines with wild-type KRAS and various EGFR expression levels (due to EGFR genetic mutations) to compare the therapeutic efficacy of cetuximab and 47Sc-DTPA-cetuximab. This evidence concerns the gene KRAS and non-small cell lung carcinoma.